home icon

right icon


right icon




Pharmaceuticals & Drugs


0.00 (0.00%)

stock change
Market Cap241 CrEPS1.5High103.2
Stock P/E66.0Net Profit Margin4.6Low98.15
home icon
The current prices are delayed, login to your account to see live prices.


Today’s Low

Today’s High



52W Low

52W High



Open Price102.6Volume1
Prev. Close102.6


Market Cap241 CrROE-25.4%
P/E Ratio(TTM)66.0EPS(TTM)-0.9
P/B Ratio3.7Dividend Yield0.0%
Industry P/E65.5Book Value27.8
Face Value10.0

About the Company

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
Parent OrganisationBafna Pharmaceuticals Ltd.Managing Director
Founded1995NSE SymbolBAFNAPH


All values are in Rs Cr


Shareholding Pattern


Peer Comparison

Company52 WeekMarket PriceP/E Ratio

Recently Viewed

No Recently Viewed Stocks

Frequently asked questions

You can buy the shares of Bafna Pharma using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.